Testing the Safety of CB-5339 in Patients With Cancer
Status:
Withdrawn
Trial end date:
2021-07-12
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of CB-5339 in treating patients
with solid tumors that has spread to other places in the body (advanced) or lymphomas.
CB-5339 may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth.